Abstract | OBJECTIVE: BACKGROUND: Two double-blind, placebo-controlled, randomized, crossover studies of zolmitriptan nasal spray in the acute treatment of cluster headache, with similar patient populations, protocol designs, doses, and clinical endpoints have been published. METHODS: In both double-blind studies, each patient was to treat 3 attacks, 1 with placebo, 1 with zolmitriptan 5 mg, and 1 with zolmitriptan 10 mg in a randomized, crossover manner. Headache intensity was rated on a 5-point scale (none to very severe). The primary endpoint was headache relief at 30 minutes post dose: reduction from moderate, severe, or very severe pain to mild or none. A multilevel, random-effects, logistic regression model was used to analyze the data. RESULTS: A total of 121 patients (100 male; 64.5% with episodic cluster headache) provided efficacy data for at least 1 attack. Zolmitriptan 5 mg and 10 mg were significantly more effective at providing headache relief at 30 minutes post treatment than placebo (odds ratio 3.48; 95% confidence interval 1.49-8.10 and odds ratio 8.68; 95% confidence interval: 3.35-22.5, respectively). For episodic cluster headache, response rates were 35.6%, 51.7%, and 73.7% for placebo, zolmitriptan 5 mg (odds ratio 2.5; P = .06 vs placebo), and 10 mg (odds ratio 9.9; P < .001 vs placebo), respectively. For chronic cluster headache, response rates were 17.2%, 41.9%, and 40.7% for placebo, zolmitriptan 5 mg (odds ratio 8.1; P = .035), and 10 mg (odds ratio 7.6; P = .046), respectively. Zolmitriptan was well tolerated in both studies with no serious adverse events reported. CONCLUSION:
|
Authors | Cecilia Hedlund, Alan M Rapoport, David W Dodick, Peter J Goadsby |
Journal | Headache
(Headache)
Vol. 49
Issue 9
Pg. 1315-23
(Oct 2009)
ISSN: 1526-4610 [Electronic] United States |
PMID | 19788472
(Publication Type: Journal Article, Meta-Analysis, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Oxazolidinones
- Serotonin Receptor Agonists
- Tryptamines
- zolmitriptan
|
Topics |
- Acute Disease
(therapy)
- Adolescent
- Adult
- Aged
- Chronic Disease
(drug therapy)
- Cluster Headache
(drug therapy)
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Oxazolidinones
(administration & dosage)
- Placebo Effect
- Serotonin Receptor Agonists
(administration & dosage)
- Treatment Outcome
- Tryptamines
(administration & dosage)
- Young Adult
|